I-CAN Biocollection

Status Completed

Clinical Trial Summary

Intracranial aneurysm (IA) is an asymptomatic cerebrovascular abnormality affecting 3.2% of the general population. The devastating complication of IA is its rupture, resulting in subarachnoid haemorrhage that can lead to severe disability and death. Unfortunately, there are neither reliable clues nor diagnostic tools to predict the formation and/or the fate of an IA in a given individual. Also, there is no pharmacological drug available to prevent the rupture of aneurysm and subsequent subarachnoid haemorrhage. Current treatments are invasive with a significant risk of procedural morbidity. Thus, still now, the management of patients with IA remains extremely challenging and still controversial. Although the pathogenesis of IA has been the subject of many studies for the last decade, the mechanisms underlying IA formation, growth and rupture are still mostly unknown and relevant animal models of IA are not available. Familial history of IA predisposes to IA formation and rupture and increasing evidence suggest a genetic component of IA formation, with heterogeneous modes of inheritance and penetrance. This project, gathering neuroradiologists, geneticists and vascular biologists, addresses the urgent need to understand the pathogenic mechanisms of IA to develop diagnostic and predictive tools of risk of IA. The investigators propose to identify IA-causing variants by whole-exome sequencing in familial forms of the disease. The investigators hypothesises that the functional analysis of the causal/susceptibility variants thus identified will provide clues to understanding the pathological mechanisms of IA formation, and the bases for developing diagnostic tools. This project aims at meeting this challenge. Based on preliminary data that already allowed to identify such a variant, and the combination of genetic and functional investigations, the specific objectives of this project are: - To identify IA-causing variants in familial forms of the disease by whole-exome sequencing; - To understand the function of these genes/variants in the formation and rupture of IA by molecular and cellular approaches and generation of relevant animal models; - To discover potential biomarkers of risk of IA formation and/or rupture.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02712892
Study type	Observational
Source	Nantes University Hospital
Contact
Status	Completed
Phase
Start date	March 3, 2016
Completion date	December 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04870047` - Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation	N/A
Recruiting	`NCT05968053` - Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
Not yet recruiting	`NCT05665309` - Interest of Pre-operative Use of 3D Printing for Endovascular Treatment of Unruptured Intracranial Aneurysms With Intrasaccular Flow Disruptor	N/A
Completed	`NCT02783339` - Neuroform Atlas Stent for Intracranial Aneurysm Treatment
Withdrawn	`NCT01194388` - Axium Coil in Completing Endovascular Aneurysm Surgery Study
Completed	`NCT00071565` - Familial Intracranial Aneurysm Study II	N/A
Recruiting	`NCT05409989` - MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study	N/A
Completed	`NCT03680742` - Contour Neurovascular System - European Pre-Market Unruptured Aneurysm	N/A
Completed	`NCT04872842` - Establishment of Online Registration Platform for Unruptured Intracranial Aneurysms Based on 100 Regional Medical Centers in China and Population Follow-up Study
Terminated	`NCT02532517` - Study to Evaluate the Safety and Effectiveness of the CODMAN ENTERPRISE® Vascular Reconstruction Device	N/A
Completed	`NCT03663257` - Study to Evaluate Cerebral AneurysmFlow Results in Occlusion
Recruiting	`NCT06189950` - Registration Trial of the Intracranial Visualized Stent for the Wide-necked Intracranial Aneurysms:REBRIDGE	N/A
Recruiting	`NCT05608122` - Establishment of Online Registration Platform for Unruptured Intracranial Aneurysms Based on Regional Medical Centers in China and Population Follow-up Study (Phase Ⅱ)
Recruiting	`NCT03661463` - Unruptured Intracranial Aneurysm Aspirin Trial (UIAAT).	Phase 2
Completed	`NCT02609867` - A Feasibility Study to Evaluate the Safety and Effectiveness of Implantation of Flowise Cerebral Flow Diverter (Flowise)	N/A
Active, not recruiting	`NCT02292017` - Prospective Packing Density With Target Coils I	N/A
Active, not recruiting	`NCT01872741` - Minipterional Versus Pterional Craniotomy	N/A
Completed	`NCT00993057` - Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia	Early Phase 1
Completed	`NCT00777088` - Pipeline for Uncoilable or Failed Aneurysms	N/A
Completed	`NCT00777907` - Complete Occlusion of Coilable Aneurysms	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

I-CAN Biocollection — I-CAN

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms